- Koga S, Ishaque M, Jeffrey Elias W, Shah BB, Murakami A, Dickson DW. Neuropathology of Parkinson's disease after focused ultrasound thalamotomy. npj Parkinson's Dis 2022;8:59.
- Schuurman PR, Bosch DA, Merkus MP, Speelman JD. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord 2008;23:1146–1153.
- Schreglmann SR, Krauss JK, Chang JW, Bhatia KP, Kägi G. Functional lesional neurosurgery for tremor: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2018;89:717–726.
- Lim S-Y, Hodaie M, Fallis M, Poon Y-Y, Mazzella F, Moro E. Gamma knife thalamotomy for disabling tremor. Arch Neurol 2010;67(5):584-588.
- Helmich RC, Hallett M, Deuschl G, Toni I, Bloem BR. Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain 2012;135:3206–3226.
- Natera-Villalba E, Pineda-Pardo JA, Del álamo M, et al. Optimal topographic characteristics of focused ultrasound unilateral thalamotomy for tremor-dominant Parkinson's disease. Mov Disord 2023;38 (Suppl 1). https://www.mdsabstracts.org/abstract/optimal-topographiccharacteristics-of-focused-ultrasound-unilateral-thalamotomy-fortremor-dominant-parkinsons-disease/. Accessed January 22, 2024

Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease"

We read the viewpoint by Drs. Boogers and Fasano with interest.¹ We agree that the target globus pallidus internus (GPi) could have been underused compared with subthalamic nucleus (STN) in deep brain stimulation (DBS) practice for patients with Parkinson's disease (PD), as the published data so far has been largely on STN DBS. Besides the many reasons to endorse a more frequent use of GPi in the future as mentioned in the article,¹ there is also a potential benefit of using GPi for the important and challenging axial symptoms as we would like to emphasize here. The symptoms of postural instability and gait disability (PIGD) were analyzed in a meta-analysis article comparing GPi with STN DBS at medication *off* and *on* status over time.² It was found that GPi is superior to STN DBS on PIGD in the long term use of DBS at medication *on* status.² Swallowing

© 2024 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

*Correspondence to: Dr. Tao Xie, Department of Neurology, The University of Chicago Medicine, 5841S. Maryland Ave., MC 2030, Chicago, IL 60637, USA; E-mail: txie@uchicagomedicine.org

Relevant conflicts of interest/financial disclosures: The authors have no relevant conflicts of interest.

Received: 12 February 2024; Accepted: 16 February 2024

Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.29782 function is another major axial symptom (although much less studied than gait and balance) where GPi DBS has demonstrated superiority to STN, as reflected in a relatively large size study and a more recent systematic review on the effect of DBS on swallowing function,^{3,4} particularly at medication *on* status,^{3,4} which is also strikingly similar to the conclusion on the effect of GPi compared with STN DBS on PIGD.²

Axial symptoms are major causes of morbidity and mortality and poor quality of life in patients with PD, particularly in the advanced disease stage or after long-term DBS therapy,^{2,4,5} when they become more and more prominent. but less and less responsive to the dopaminergic medications and DBS therapy, likely because they are largely due to deficits caused by non-dopaminergic mechanisms.⁶ It is hard to tell whether the worsening of axial symptoms is because of disease progression, DBS stimulation related side effects (possibly less so in GPi given its much larger size than STN), medication changes (given the significant reduction of the dopaminergic medications post-surgically in patients with STN, but not much in GPi DBS), or the combination of all. This, along with the favorable effect of GPi DBS on mood, cognitive function, and dyskinesia compared with STN DBS,^{1,7} would further suggest that GPi should be more frequently used, particularly also as mentioned that the journey post implantation could be different or more challenging for STN, and that we need to make our decision based on real world data, which can also be affected by the currently implicit selection bias of the targets.¹ The possible superiority of GPi DBS on the important challenging axial symptoms of gait, balance, and swallowing function here could possibly further motivate an increased use of GPi,²⁻⁴ which will help us to gather more information on the use of GPi and yield a better assessment and selection of the targets for DBS in the future.

Acknowledgments: We thank all patients and families for their engagement in our studies.

Data Availability Statement

Data sharing not applicable - no new data generated.

Tao Xie, MD, PhD, ^{1*} ¹ and Peter C. Warnke, MD² ¹Department of Neurology, University of Chicago Medicine, Chicago, Illinois, USA, and ²Department of Neurological Surgery, University of Chicago Medicine, Chicago, Illinois, USA

References

- 1. Boogers A, Fasano A. Transatlantic viewpoint on the role of pallidal stimulation for Parkinson's disease. Mov Disord 2024;39:36–39.
- St. George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology 2010;75:1292–1299.
- 3. Troche MS, Brandimore AE, Foote KD, Morishita T, Chen D, Hegland KW, Okun MS. Swallowing outcomes following unilateral STN vs GPi surgery: a retrospective analysis. Dysphagia 2014;29: 425-431.

- Yu H, Takahashi K, Bloom L, Quaynor SD, Xie T. Effect of deep brain stimulation on swallowing function: a systematic review. Front Neurol 2020;11:547.
- Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190–199.
- Bohnen NI, Müller ML, Koeppe RA, Studenski SA, Kilbourn MA, Albin RL. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009;73:1670–1676.
- Williams NR, Foote KD, Okun MS. Subthalamic nucleus versus globus pallidus internus deep brain stimulation: translating the rematch into clinical practice. Mov Disord Clin Pract 2014;1: 24-35.

Reply to: Comment on: A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease

We thank Xie and Warnke for their comment¹ on our viewpoint,² in which they raise a possible additional benefit of deep brain stimulation (DBS) targeting the globus pallidus internus (GPi) compared to the subthalamus (STN). Xie and Warnke¹ reference a few different studies showing that postural instability, gait disorder, and swallowing function have a better outcome in cohorts receiving GPi DBS as opposed to STN.³⁻⁵ Our clinical experience is aligned with these findings. Interestingly, one of these studies investigated the impact on axial motor function of unilateral GPi versus unilateral STN DBS.⁴ Nowadays, especially when targeting the STN, bilateral procedures have become the standard-of-care, even if staged. Therefore, we argue that the safety profile of GPi is even more beneficial when considering bilateral procedures.

© 2024 International Parkinson and Movement Disorder Society.

Key Words: deep brain stimulation, Parkinson's disease, subthalamic stimulation, pallidal stimulation

*Correspondence to: Dr. Alfonso Fasano, Movement Disorders Centre, Toronto Western Hospital 399 Bathurst St, 7 Mc410, Toronto, Ontario, Canada; E-mail: alfonso.fasano@uhn.ca; alfonso.fasano@gmail.com

Relevant conflicts of interest/financial disclosures: The authors have no conflicts of interest to declare. A.B. reports receiving honoraria from American Academy of Neurology and AbbVie, consultancy fees from AbbVie, Abbott, and Boston Scientific, and research grant from Fernand Lazard Foundation. All disclosures are not relevant to the paper. A.F. reports the following consultancies from AbbVie, Ceregate, Medtronic, Boston Scientific, Iota, Inbrain, Inbrain Pharma; honoraria from AbbVie, Medtronic, Boston Scientific, Sunovion, Chiesi farmaceutici, UCB, Ipsen; and grants from University of Toronto, Weston foundation, AbbVie, Medtronic, Boston Scientific, and Canadian Institutes of Health Research.

Funding agency: This work was partly supported by the Chair in Neuromodulation (A.F.) at University of Toronto and University Health Network, Toronto, ON, Canada.

Received: 22 February 2024; Accepted: 23 February 2024

Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.29780 It is well recognized that axial motor function plays a major role in determining the mood and quality of life of PD patients. Perhaps not surprisingly, a systematic literature review, meanwhile published, concluded that these metrics are more favorable in patients undergoing GPi DBS compared to STN DBS.⁶ Specifically, the authors concluded that the GPi cohort demonstrated a greater improvement in terms of Beck Depression Inventory as well as depression and anxiety subscores of the Hospital Anxiety and Depression Scale. Moreover, after a follow-up of 6 months or more, both cohorts showed an improvement in the Parkinson's Disease Questionnaire 39 (PDQ-39), although a larger effect was seen when targeting the GPi. A similar trend was seen in the emotions subscore of PDQ-39.

In conclusion, the points raised by Xie and Warnke¹ further strengthen the main message of our viewpoint, namely that patient-centered and patient-reported outcomes are essential when assessing the effect of DBS in people with PD.

Data Availability Statement

Not applicable.

Alexandra Boogers, MD, PhD, ¹ ¹ and Alfonso Fasano, MD, PhD, FAAN^{1,2,3*} ¹ ¹Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, UHN, and Division of Neurology, University of Toronto, Toronto, Ontario, Canada, ²Krembil Brain Institute, Toronto, Ontario, Canada, and ³Center for Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, Ontario, Canada

References

- Xie T, Warnke P. Comment on "a transatlantic viewpoint on the role of pallidal stimulation for Parkinson's disease.". Movement Disorders. Published online 2024.
- 2. Boogers A, Fasano A. A transatlantic viewpoint on the role of pallidal stimulation for Parkinson's disease. Mov Disord 2024;39(1):36–39. https://doi.org/10.1002/mds.29656
- 3. St George R, Nutt J, Burchiel K, Horak F, Surgery N. A Meta-Regression of the Long-Term Effects of Deep Brain Stimulation on Balance and Gait in PD; 2010.
- Troche MS, Brandimore AE, Foote KD, et al. Swallowing outcomes following unilateral STN vs. GPi surgery: a retrospective analysis. Dysphagia 2014;29(4):425–431. https://doi.org/10.1007/s00455-014-9522-0
- Yu H, Takahashi K, Bloom L, Quaynor SD, Xie T. Effect of deep brain stimulation on swallowing function: a systematic review. Front Neurol 2020;11:547. https://doi.org/10.3389/fneur.2020.00547
- El Ghazal N, Nakanishi H, Martinez-Nunez AE, et al. The effects of deep brain stimulation on mood and quality of life in Parkinson's disease: a systematic review and meta-analysis. Cureus Published online August 2023;26:1–29. https://doi.org/10.7759/ cureus.44177